Primary Prevention of Clostridioides difficile Infection With Oral Vancomycin in Pediatric Hematopoietic Stem Cell Transplant Patients

Authors

• Heather Valdin, LSU Health Sciences Center - New OrleansFollow
• Blake Gray, LSU Health Sciences Center - New Orleans
• G. Cook, Manning Family Children's, New Orleans, LA
• M. Creamer, Manning Family Children's, New Orleans, LA
• Lolie Yu, LSU Health Sciences Center - New OrleansFollow
• Zachary T. LeBlanc, LSU Health Sciences Center - New OrleansFollow

Document Type

Article

Publication Date

12-3-2025

Publication Title

Pediatric Transplantation

Abstract

Background: Clostridioides difficile infection (CDI) poses a significant risk to pediatric hematopoietic stem cell transplant (HSCT) due to microbiome disruption, mucosal injury, and graft versus host disease (GVHD). While oral vancomycin prophylaxis (OVP) is effective for preventing recurrent CDI, evidence for its role in preventing initial infection is limited. Our institution employs empiric OVP during the first HSCT admission to prevent initial CDI. Objectives: We sought to describe the incidence of CDI among pediatric HSCT recipients receiving OVP and to evaluate secondary outcomes related to OVP exposure. Methods: We conducted a single center, retrospective observational study of 84 pediatric HSCT recipients at our institution receiving OVP during their initial transplant admission. Chart review captured demographics, transplant information, and clinical outcomes. The primary outcome was CDI incidence during hospitalization. Secondary outcomes included VRE infections, refractory CDI following cessation of OVP, and acute GI GVHD. Results: Only one patient developed CDI (1.19%) while on OVP, despite universal exposure to high-risk antibiotics among the entire cohort. No VRE infections were observed. Rates of GI aGVHD were consistent with national averages. Nine patients (10.7%) developed CDI after discontinuing OVP, all managed with standard treatment. Conclusion: Empiric OVP during pediatric HSCT hospitalization was associated with a markedly low CDI incidence. Despite theoretical risks of microbiome disruption, no adverse effects were identified in this cohort, including long-term follow-up beyond 5 years. These findings support the safety and potential efficacy of OVP as primary CDI prophylaxis in pediatric HSCT patients.

PubMed ID

41339713

Volume

29

Issue

8

Rights

© 2025 Wiley Periodicals LLC.

Recommended Citation

Valdin, Heather; Gray, Blake; Cook, G.; Creamer, M.; Yu, Lolie; and LeBlanc, Zachary T., "Primary Prevention of Clostridioides difficile Infection With Oral Vancomycin in Pediatric Hematopoietic Stem Cell Transplant Patients" (2025). School of Medicine Faculty Publications. 4769.
https://digitalscholar.lsuhsc.edu/som_facpubs/4769
10.1111/petr.70246